menu
    • menu
    [{"orgOrder":0,"company":"MARATHON PHARMS","sponsor":"Aquestive Therapeutics","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI\u2122 Monetization","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"Diazepam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"MARATHON PHARMS","amount2":0.089999999999999997,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.089999999999999997,"dosageForm":"Buccal Film","sponsorNew":"MARATHON PHARMS \/ Marathon","highestDevelopmentStatusID":"12","companyTruncated":"MARATHON PHARMS \/ Marathon"}]

    Find Clinical Drug Pipeline Developments & Deals by MARATHON PHARMS

    Menu

    MARATHON PHARMS

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MARATHON PHARMS

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            MARATHON PHARMS

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diazepam

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Aquestive Therapeutics

                            Deal Size : $85.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization

                            Details : The proceeds will help to execute on advancing company's key clinical and commercial initiatives, including the resubmission of its NDA for FDA approval of lead product Libervant™ Buccal Film and ongoing clinical trial for AQST-108.

                            Brand Name : Libervant

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 23, 2020

                            Lead Product(s) : Diazepam

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Aquestive Therapeutics

                            Deal Size : $85.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth